secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001999480-25-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience FY2024 net loss $61.4M; cash $169M; two directors departing
-----------------------------------------------------------------------------

- Net loss $61.4M for FY2024 vs $36.3M in 2023; R&D expense $47M, G&A $21.6M.
- Cash and equivalents $169M as of Dec 31, 2024; expected to fund operations into 2028.
- Directors Jeff Chen and Maha Radhakrishnan will not stand for re-election at 2025 annual meeting; board size to shrink from 7 to 5.
- ALTO-300 Phase 2b MDD trial interim analysis positive; topline results expected mid-2026.
- ALTO-203 Phase 2 MDD trial enrollment complete; topline data expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/0001999480-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/alto-20250317.htm
  HTML page:      https://secwatch.observer/filing/0001999480-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer